CLINICAL RESEARCH: HEART FAILURE
The Effects of KW-3902, an Adenosine A1-Receptor Antagonist,on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance
Michael M. Givertz, MD, FACC*,1,*,
Barry M. Massie, MD, FACC ,2,
Tara K. Fields, BA ,3,
Leeanne L. Pearson, RN, BS,3,
Howard C. Dittrich, MD, FACC, ,3 on behalf of the CKI-201 and CKI-202 Investigators
* Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
Cardiology Division, San Francisco Veterans Affairs Medical Center, San Francisco, California
NovaCardia, Inc., San Diego, California
University of California, San Diego, California.
Manuscript received March 5, 2007;
revised manuscript received May 22, 2007,
accepted July 11, 2007.
* Reprint requests and correspondence: Dr. Michael M. Givertz, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, Massachusetts 02115. (Email: mgivertz{at}partners.org).
Objectives: This study sought to evaluate the dose-dependent effects of adenosine A1-receptor blockade on diuresis and renal function in patients with acute decompensated heart failure (ADHF) and renal impairment or diuretic resistance.
Background: Intravenous loop diuretics are the mainstay of therapy for patients with ADHF. Treatment, however, may be complicated by diuretic resistance and/or worsening renal function.
Methods: We carried out a pair of randomized, double-blind, placebo-controlled, proof-of-concept studies in 2 clinically challenging ADHF populations.
Results: In the ADHF protocol, 146 patients with volume overload and an estimated creatinine clearance (CrCl) of 20 to 80 ml/min were randomized to placebo or 1 of 4 doses of KW-3902 (rolofylline) infused over 2 h daily for up to 3 days. On day 1, KW-3902 monotherapy increased urine output during the first 6 h (445, 531, 631, and 570 ml in the 2.5-, 15-, 30-, and 60-mg groups, respectively) compared with placebo (374 ml; p = 0.02). On day 2, serum creatinine decreased in all KW-3902 groups and increased with placebo (p = 0.04). By day 4 or day of discharge if earlier, intravenous furosemide administration tended to be lower in the KW-3902 groups compared with placebo (p = 0.10). In the diuretic-resistant protocol, 35 patients with an average CrCl of 34 ml/min were randomized to a single infusion of placebo, 10, 30, or 60 mg of KW-3902. Compared with placebo, KW-3902 increased hourly urine volume and estimated CrCl with peak effects occurring at 2 to 3 h and at 24 h, respectively. Adverse events were not different between placebo and KW-3902.
Conclusions: In patients with ADHF and volume overload, KW-3902, an adenosine A1-receptor antagonist, enhances the response to loop diuretics and may have a renal protective effect.
|
Abbreviations and Acronyms
| | ADHF = acute decompensated heart failure | | CrCl = creatinine clearance | | GFR = glomerular filtration rate | | IV = intravenous | | NYHA = New York Heart Association | | SBP = systolic blood pressure | | SCr = serum creatinine |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 50: A31-A32.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
E. K. Jackson, D. Cheng, S. P. Tofovic, and Z. Mi
Endogenous adenosine contributes to renal sympathetic neurotransmission via postjunctional A1 receptor-mediated coincident signaling
Am J Physiol Renal Physiol,
February 1, 2012;
302(4):
F466 - F476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Metra, C. M. O'Connor, B. A. Davison, J. G. F. Cleland, P. Ponikowski, J. R. Teerlink, A. A. Voors, M. M. Givertz, G. A. Mansoor, D. M. Bloomfield, et al.
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study
Eur. Heart J.,
June 2, 2011;
32(12):
1519 - 1534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Gottlieb, B. Ticho, A. Deykin, W. T. Abraham, D. DeNofrio, S. D. Russell, D. Chapman, W. Smith, S. Goldman, and I. Thomas
Effects of BG9928, an Adenosine A1 Receptor Antagonist, in Patients With Congestive Heart Failure
J. Clin. Pharmacol.,
June 1, 2011;
51(6):
899 - 907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Voors, H. C. Dittrich, B. M. Massie, P. DeLucca, G. A. Mansoor, M. Metra, G. Cotter, B. D. Weatherley, P. Ponikowski, J. R. Teerlink, et al.
Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction: Results From PROTECT (Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function)
J. Am. Coll. Cardiol.,
May 10, 2011;
57(19):
1899 - 1907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Clark, A. P. Coletta, and J. G. F. Cleland
41 Therapeutic control of fluid balance in chronic heart failure
Oxford Textbook of Heart Failure,
January 1, 2011;
1(1):
med-9780199577729-chapter - med-9780199577729-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Ponikowski, V. Mitrovic, C. M. O'Connor, H. Dittrich, G. Cotter, B. M. Massie, M. M. Givertz, E. Chen, M. Murray, B. D. Weatherley, et al.
Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function
Eur J Heart Fail,
November 1, 2010;
12(11):
1238 - 1246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Bell, Z. Luo, and W. J. Welch
Glomerular tubular balance is suppressed in adenosine type 1 receptor-deficient mice
Am J Physiol Renal Physiol,
November 1, 2010;
299(5):
F1158 - F1163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Davenport, S. D. Anker, A. Mebazaa, A. Palazzuoli, G. Vescovo, R. Bellomo, P. Ponikowski, I. Anand, N. Aspromonte, S. Bagshaw, et al.
ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference
Nephrol. Dial. Transplant.,
July 1, 2010;
25(7):
2077 - 2089.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Metra, J. G. Cleland, B. Davison Weatherley, H. C. Dittrich, M. M. Givertz, B. M. Massie, C. M. O'Connor, P. Ponikowski, J. R. Teerlink, A. A. Voors, et al.
Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study
Eur J Heart Fail,
May 1, 2010;
12(5):
499 - 507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. W. Tang and W. Mullens
Cardiorenal syndrome in decompensated heart failure
Heart,
February 1, 2010;
96(4):
255 - 260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. V. Ramani, P. A. Uber, and M. R. Mehra
Chronic Heart Failure: Contemporary Diagnosis and Management
Mayo Clin. Proc.,
February 1, 2010;
85(2):
180 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Givertz
Adenosine A1 Receptor Antagonists at a Fork in the Road
Circ Heart Fail,
November 1, 2009;
2(6):
519 - 522.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Mitrovic, P. Seferovic, S. Dodic, M. Krotin, A. Neskovic, K. Dickstein, H. de Voogd, C. Bocker, D. Ziegler, M. Godes, et al.
Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure
Circ Heart Fail,
November 1, 2009;
2(6):
523 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F Franceschi, J-C Deharo, R Giorgi, Y By, C Monserrat, J Condo, Z Ibrahim, A Saadjian, and R Guieu
Peripheral plasma adenosine release in patients with chronic heart failure
Heart,
April 1, 2009;
95(8):
651 - 655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gheorghiade and P. S. Pang
Acute Heart Failure Syndromes
J. Am. Coll. Cardiol.,
February 17, 2009;
53(7):
557 - 573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Johnson
Implications of biosimilars for the future
Am. J. Health Syst. Pharm.,
July 15, 2008;
65(14_Supplement_6):
S16 - S22.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Himmelfarb, M. Joannidis, B. Molitoris, M. Schietz, M. D. Okusa, D. Warnock, F. Laghi, S. L. Goldstein, R. Prielipp, C. R. Parikh, et al.
Evaluation and Initial Management of Acute Kidney Injury
Clin. J. Am. Soc. Nephrol.,
July 1, 2008;
3(4):
962 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. De Luca, A. Mebazaa, G. Filippatos, J. T. Parissis, M. Bohm, A. A. Voors, M. Nieminen, F. Zannad, A. Rhodes, A. El-Banayosy, et al.
Overview of emerging pharmacologic agents for acute heart failure syndromes
Eur J Heart Fail,
February 1, 2008;
10(2):
201 - 213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the Year in JACC 2007
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
